Xu H - Search Results

1

New insights into HER2-low breast cancer brain metastasis: A retrospective analysis.

Xu H, Wang Y, Li L, Han Y, Wu Y, Sa Q, Xu B, Wang J. Xu H, et al. Among authors: xu b. Breast. 2024 Feb;73:103669. doi: 10.1016/j.breast.2023.103669. Epub 2024 Jan 1. Breast. 2024. PMID: 38176304 Free PMC article.

2

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.

Han Y, Wu Y, Xu H, Wang J, Xu B. Han Y, et al. Among authors: xu b, xu h. Int J Clin Oncol. 2022 Apr;27(4):707-716. doi: 10.1007/s10147-022-02115-x. Epub 2022 Jan 18. Int J Clin Oncol. 2022. PMID: 35041101 Free PMC article.

3

Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.

Wu Y, Han Y, Li Q, Zhang P, Yuan P, Luo Y, Fan Y, Chen S, Cai R, Li Q, Xu H, Wang Y, Ma F, Wang J, Xu B. Wu Y, et al. Among authors: xu b, xu h. Breast Cancer Res Treat. 2022 Jun;193(2):381-392. doi: 10.1007/s10549-022-06559-7. Epub 2022 Mar 16. Breast Cancer Res Treat. 2022. PMID: 35297009

4

[Relationship between obesity and death by multi-morbidity status in older adults in China].

Su HX, Chen ZS, Xu HW, Luo Y, Wang KP, Hu YH, Xu BB. Su HX, et al. Among authors: xu hw, xu bb. Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Mar 10;43(3):324-329. doi: 10.3760/cma.j.cn112338-20210831-00697. Zhonghua Liu Xing Bing Xue Za Zhi. 2022. PMID: 35345285 Chinese.

5

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.

Xu H, Han Y, Wu Y, Wang Y, Wang J, Xu B. Xu H, et al. Among authors: xu b. Cancer Med. 2022 Dec;11(23):4501-4512. doi: 10.1002/cam4.4839. Epub 2022 May 22. Cancer Med. 2022. PMID: 35598300 Free PMC article. Clinical Trial.

6

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience.

Xu H, Han Y, Wu Y, Wang Y, Li Q, Zhang P, Yuan P, Luo Y, Fan Y, Chen S, Cai R, Li Q, Ma F, Xu B, Wang J. Xu H, et al. Among authors: xu b. Front Oncol. 2022 Jun 16;12:906011. doi: 10.3389/fonc.2022.906011. eCollection 2022. Front Oncol. 2022. PMID: 35785207 Free PMC article.

7

Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis.

Wang Y, Xu H, Han Y, Wu Y, Wang J. Wang Y, et al. Among authors: xu h. Cancers (Basel). 2022 Jul 11;14(14):3372. doi: 10.3390/cancers14143372. Cancers (Basel). 2022. PMID: 35884431 Free PMC article. Review.

8

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.

Xu H, Wang Y, Han Y, Wu Y, Wang J, Xu B. Xu H, et al. Among authors: xu b. Front Oncol. 2022 Aug 24;12:956464. doi: 10.3389/fonc.2022.956464. eCollection 2022. Front Oncol. 2022. PMID: 36091147 Free PMC article.

9

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis.

Han Y, Wang J, Wu Y, Xu H, Wang Y, Xu B. Han Y, et al. Among authors: xu b, xu h. Curr Oncol. 2022 Nov 25;29(12):9172-9180. doi: 10.3390/curroncol29120718. Curr Oncol. 2022. PMID: 36547132 Free PMC article. Review.

10

Preface to Special Issue: Cancer epidemiology, risk factors and screening.

Xu B, Xu H. Xu B, et al. Among authors: xu h. Chin J Cancer Res. 2023 Dec 30;35(6):563-564. doi: 10.21147/j.issn.1000-9604.2023.06.01. Chin J Cancer Res. 2023. PMID: 38204444 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45,645 results

Search Page

Filters